Lung function of people with pulmonary arterial hypertension at sea level and high altitude
Compares lung function after returning to high altitude in people with pulmonary arterial hypertension.
Plain-language title generated from the registry record
Registry title: Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Patients With Pulmonary Arterial Hypertension PAH
Key facts
- Where
- Zurich, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07804576, who can take part
Where in Switzerland
- University Hospital of ZurichZurich, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Silvia Ulrich Somaini
- Trial code
- NCT07804576
- Record updated
- 4 September 2026
- Original description
To study the effect of a re-ascent to high altitude (Quito Ecuador: 2850m) after a one-week stay at sea level (after prior descent from 2850m) on lung function and pulmonary resistance/reactance in patients with pulmonary arterial disease PAH, who live permanently > 2600m.Read full original descriptionShow less
Effect of a One-week Descent From 2850m to Sea Level and Re-ascent in Patients With Pulmonary Arterial Hypertension and Healthy Controls Permanently Living > 2600m on Pulmonary Hemodynamics, Exercise Capacity, Blood Oxygenation, Sleep Disordered Breathing and Further Outcomes
To study the effect of a re-ascent to high altitude (Quito Ecuador: 2850m) after a one-week stay at sea level (after prior descent from 2850m) on lung function and pulmonary resistance/reactance in patients with pulmonary arterial disease PAH, who live permanently > 2600m.
Inclusion: Adult patients aged 18-80 years and of all genders; Permanent residence > 2600 m; Diagnosis of pulmonary arterial hypertension PAH (PAHHA-Group) according to guidelines; Patients are stable on therapy; NYHA (new york heart association) functional class I-III; written informed consent to participate in the study.
Exclusion: Patients with moderate to severe concomitant lung disease (FEV1<70% or forced vital capacity <70%), severe parenchymal lung disease, severe smokers (>20 cigarettes/day); unstable condition; Relevant concomitant other disease of the heart, kidney, liver, blood (anemia hemoglobin<11 g/dl); Age <18 years or >80 years; Patients who cannot follow the study investigations; Patient permanently living < 2600m; Patients who traveled and stayed overnight at altitudes <2000 m in the past 4 weeks; Severely hypoxemic patients at Quito permanently having persistent SpO2 (oxygen saturation by pulseoximetry) <80% on ambient air; Patient with a non-corrected ventricular septum defect.